This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Type of economic evaluation
Cost-utility analysis
Study objective
This study evaluated the cost-effectiveness of systematic integrated depression screening and treatment for patients diagnosed with cancer, who were attending specialist cancer out-patient services and who had a life expectancy of one year or more.
Interventions
Systematic integrated depression management was compared with usual care. This began with two stages of identification. First, screening staff assisted patients with completion of the Hospital Anxiety and Depression Scale (HADS) while waiting for their clinic appointment. Second, patients with a HADS score of 15 or more were phoned at home, and a brief diagnostic interview for major depression was administered. This was followed by Depression Care for People with Cancer (DCPC), a multi-component, systematic, team-delivered treatment programme integrated with cancer care.
Usual care was the identification of major depression by the patient's general practitioner (GP) using their clinical skills, and their GP's chosen treatment from monitoring, antidepressant medication, or referral for psychological therapy.
Location/setting
UK/secondary care.
Methods

Analytical approach:
A two-part model was used to analyse the published clinical evidence. The first part was a decision tree for true and false identification of patients with major depression. The second part was a Markov model of the transitions between depression and treatment health states. The time horizon was five years. The authors stated that they adopted a UK NHS and Personal Social Services perspective.
Effectiveness data:
The main effectiveness data included the accuracy of the screening tests, and the remission and relapse probabilities during treatment. Test accuracy was from a published meta-analysis and other published data, and the probabilities were from a trial. Other published data were used for the remaining clinical parameters. The second stage of screening, the brief diagnostic interview, was assumed to have 100% specificity.
